Supplement your learning on Ultrasound excellence in Beyond ultrasound: MRI in gynecological imaging
Join us for this engaging and informative course. Together with a panel of expert speakers from around the world, they will dive into the most challenging and evolving aspects of Advances in artificial intelligence for gynecological ultrasound. This course offers attendees a valuable opportunity to gain a comprehensive understanding of the new advances in this area and learn how to apply them in practical situations.
Explore the topic before you attend our course
In order to make the most of this learning experience and help you achieve your learning objectives, we have prepared a path to guide you from the essentials to our course’s topics through ISUOG resources. The material below, will take you from the most basics to a more comprehensive view of Advances in artificial intelligence for gynecological ultrasound, some open to everyone and some available only to ISUOG members –some may even grant you CME points:
Some of these activities are exclusively available to our members. Become a member today.
VISUOG
Epithelial origin
Explore the sub-sections on Invasive epithelial tumors, Benign epithelial tumors and Transitional cells tumors.
Germ cells tumors
Explore the sub-sections on Rare germ cells tumors, Benign germ cells tumors and Malignant germ cells.
Stromal and sex-cord cells tumors
Explore a sub-section on specialized stromal cell tumors and a chapter on ovarian fibroma and fibrothecoma.
Borderline ovarian tumor (BOT)
Borderline ovarian tumors (BOTs) are epithelial tumors with low grade of malignancy. BOTs account for 10–15% of epithelial ovarian tumors. These tumors occur in younger women, with almost 30% of patients younger than 40 years, and are often diagnosed at an earlier stage than invasive carcinomas.
Metastases to the ovary
The ovary is a common site of metastases from malignant tumors. Most metastases in the ovaries originate in the gastrointestinal tract or the breast. The distinction between primary and metastatic ovarian neoplasm is of critical importance, since surgical cytoreduction is the treatment of choice for the former.
Uterine sarcomas
Uterine sarcomas are rare malignant tumors arising from the mesenchymal tissues of the uterus, i.e. the endometrial stroma, uterine muscle and connective tissue. They represent 1% of female genital tract malignancies and 3-7% of all uterine malignances.
Patient Information
Borderline Ovarian Tumor
This leaflet is to help you understand what Borderline Ovarian Tumor is, how does it happen, what tests you need and what are the long term implications of the diagnosis.
Epithelial ovarian carcinoma
This leaflet is to help you understand what Epithelial ovarian carcinoma is, what tests you need and the implication of being diagnosed with Epithelial ovarian carcinoma for you, your baby and your family.
Granulosa cell tumor
This leaflet is to help you understand what Granulosa cell tumor is, how does it happen, what tests you need and what are the long term implications of the diagnosis.
Malignant struma ovarii
This leaflet is to help you understand what Malignant struma ovarii is, how does it happen, what tests you need and what are the long term implications of the diagnosis.
Metastatic Lesions
This leaflet is to help you understand what Metastatic Lesions are, what causes them, what tests you need and what the implications of being diagnosed with a tumor.
Cervical cancer
This leaflet is to help you understand what cervical cancer is, what tests you need and the implication of being diagnosed and what treatment options are available to you.
Endometrial Cancer
This leaflet is to help you understand what endometrial cancer is and what causes it, how it can be diagnosed and the treatments available to you.
UOG articles
Differentiating high- and low-grade serous ovarian carcinoma using radiomics: a pilot study
F. Ciccarone, G. Zinicola, E. H. Tran, G. Baldassari, E. Boccia, C. Nero, F. Moro, T. Pasciuto, G. Scambia, G. Ferrandina, A. Fagotti, A. C. Testa, D. Lorusso, Collaborators
First published: 13 September 2026
F. Moro, M. Ciancia, S. di Berardino, G. Baldassari, F. Mascilini, F. Ciccarone, C. Nero, H. E. Tran, T. Pasciuto, L. Boldrini, D. Giannarelli, A. Ledger, T. Bourne, W. Froyman, D. Timmerman, L. Valentin, A. Fagotti, A. C. Testa
First published: 30 March 2026
F. Ciccarone, A. Rizzi, A. Biscione, G. Baldassari, E. H. Tran, T. Pasciuto, F. Moro, G. Zinicola, F. Buonomo, M. Colombin, F. Ghezzi, J. Casarin, R. Mancari, F. Borella, A. Kardhashi, M. Roccio, L. Savelli, R. Cioffi, F. Fanfani, G. Ferrandina, G. Scambia, L. Valentin, D. Lorusso, A. C. Testa
First published: 06 March 2026
E. Lems, A. H. Koch, E. J. L. G. Delvaux, J. C. Leemans, M. Y. Bongers, C. A. R. Lok, B. L. Ramaekers, P. M. A. J. Geomini
First published: 04 December 2025
A. Deslandes, J. C. Avery, H.-T. Chen, M. Leonardi, S. Knox, G. Lo, R. O'Hara, G. Condous, M. L. Hull, Collaborators
First published: 24 January 2025
F. Moro, M. T. Giudice, M. Ciancia, D. Zace, G. Baldassari, M. Vagni, H. E. Tran, G. Scambia, A. C. Testa
First published: 31 January 2025
F. Moro, M. Vagni, H. E. Tran, F. Bernardini, F. Mascilini, F. Ciccarone, C. Nero, D. Giannarelli, L. Boldrini, A. Fagotti, G. Scambia, L. Valentin, A. C. Testa
First published: 15 May 2024
F. Moro, M. Albanese, L. Boldrini, V. Chiappa, J. Lenkowicz, F. Bertolina, F. Mascilini, R. Moroni, M. A. Gambacorta, F. Raspagliesi, G. Scambia, A. C. Testa, F. Fanfani
First published: 29 October 2021
Learning modules
Diagnosis of ovarian masses: Future lines of research
T. Bourne 2026
Using AI in the diagnostic model: the development of ADNEX-AI
D. Timmerman 2025
AI in Adnexal Masses
A. Testa 2025
Radiomics and how it may contribute to AI Solutions
J. Barcroft 2025
